Condition: Acute Myeloid Leukemia · Genetic Predisposition to Disease · Sponsor: Assistance Publique - Hôpitaux de Paris
Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms. The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.
This description comes directly from the study's public registry record.
Arnaud PETIT, Pr · +33 1 44 73 53 14 · arnaud.petit@aphp.fr
Jérôme Lambert, Pr · 142499742 · jerome.lambert@u-paris.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie site Sud | Amiens, France | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| Hopital Minjoz | Besançon, France | Recruiting |
| CHU Pellegrin | Bordeaux, France | Recruiting |
| CHRU Morvan | Brest, France | Recruiting |
| CHU Caen | Caen, France | Recruiting |
| CHU Estaing | Clermont-Ferrand, France | Recruiting |
| CHU Francois Mitterand | Dijon, France | Recruiting |
| CHU Grenoble | Grenoble, France | Recruiting |
| CHU de la Réunion | La Réunion, France | Recruiting |
| Hopital Jeanne de Flandre - CHRU | Lille, France | Recruiting |
| CHU Limoges | Limoges, France | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05772559